antiretroviral drugs

DOSE IN NORMAL RENAL FUNCTION

PHARMACOKINETICS

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

IMPORTANT DRUG INTERACTIONS

plasma levels of amiodarone and lidocaine

drugs increased when given with
clarithromycin; rifabutin concentration
increased – reduce dose of rifabutin;
rifampicin reduces atazanavir
concentration – avoid concomitant use;
avoid concomitant use with telithromycin
in severe renal and hepatic impairment

St John’s wort – avoid concomitant use

administration with artemether/
lumefantrine

metabolism of aripiprazole – reduce
dose of aripiprazole; possibly increased
concentration of pimozide – avoid
concomitant use

efavirenz –increase dose of atazanavir;
concentration possibly reduced by
nevirapine – avoid concomitant use;
saquinavir concentration increased;
concentration reduced by tenofovir and
tenofovir concentration possibly increased;
avoid concomitant use with indinavir
C

of diltiazem increased – reduce dose of
diltiazem; possibly increased verapamil
concentration

concentration of ciclosporin

irinotecan – increased risk of toxicity

concentration of ergot alkaloids – avoid
concomitant use
Oestrogens: increased concentration of

ethinylestradiol – avoid concomitant use
Sildenafil: possibly increased side effects

of sildenafil

concentration of sirolimus
Statins: avoid concomitant use with

simvastatin – increased risk of myopathy;
possibly increased risk of myopathy with
atorvastatin
t is not licensed for use by anyone else.

concentration of tacrolimus

significantly reduced by omeprazole and
esomeprazole and possibly other proton
pump inhibitors – avoid concomitant
use; concentration possibly reduced by
histamine H2 antagonists

ADMINISTRATION

Reconstition

Route

Rate of Administration

Comments

used in combination